Nuvilex (NVLX) And Translational Drug Development (TD2) Begin Preparations For US-Based Studies On Symptoms Associated With Pancreatic Cancer
5/21/2014 9:19:48 AM
SILVER SPRING, Md., May 21, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that, together with Translational Drug Development (TD2) in Scottsdale, Arizona, preparations have begun for US-based preclinical and then clinical studies on the unbearable pain and the accumulation of fluid in the abdominal cavity which are two commonly occurring symptoms associated with advanced pancreatic cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by